Is bioMérieux profitable in 2026?

Yes on a full-year basis: FY2025 net income was 397 million euros with free cash flow of 462 million euros. However Q1 2026 sales missed forecasts, triggering a guidance cut and a 15% single-day stock drop on April 23, 2026, raising near-term margin pressure questions.

Could AI replace bioMérieux's diagnostics business?

No. bioMérieux's core products, BIOFIRE, VIDAS and VITEK, are FDA and CE-cleared regulated wet-lab hardware and reagent systems. AI is being layered in as a feature, such as the April 2025 Mila partnership on antimicrobial-resistance prediction, not a replacement for physical diagnostic testing.

Who owns bioMérieux?

Institut Mérieux, the Mérieux family holding company, controls roughly 59% of bioMérieux's share capital and a majority of voting rights as of January 2026, via Compagnie Mérieux Alliance SAS. The company has traded publicly on Euronext Paris under ticker BIM since 2004.

Is bioMérieux stock down in 2026?

Yes, significantly. Shares fell over 15% on April 23, 2026 after a Q1 sales miss and guidance cut, and by July 5, 2026 the stock traded near its 52-week low of about 67.75 euros, down roughly 43% year-over-year from a high of 128.30 euros.

Who is bioMérieux's biggest competitor?

Roche Diagnostics, holding roughly 20% of the global IVD market as of mid-2026, alongside Abbott, Danaher (via Cepheid), BD and DiaSorin. bioMérieux's immunoassay segment fell 6% in FY2025 partly due to point-of-care competition in that space.

Will bioMérieux's H1 2026 results show recovery?

Unclear from prior data alone; H1 2026 results are due July 28, 2026, following a Q1 2026 report that showed North America organic sales down 6.9% and Asia-Pacific down 7.6%, after which full-year guidance was cut and shares fell over 15% on April 23, 2026.

Biotech tools companies · France

bioMérieux SA

biomerieux.com ↗

Makes PCR panel machines and reagents hospitals use to diagnose infections fast.

Defensible for now

Assessed 24 July 2026 · Evidence as of 24 July 2026

Real protection, with named pressure against it.

On the recordSince 24 July 2026 · Checkable from July 28, 2026 · Every call on the record Checkpoint: H1 2026 results, will show if North America and China declines are cyclical or ongoing

The call

bioMérieux sells diagnostic machines that hospitals and labs use to run blood tests and identify infections. The company is profitable and has strong lock-in because hospitals buy its machines then must buy its test cartridges from them for years, and competitors like Roche and Abbott cannot easily convince customers to switch without replacing expensive hardware. The real question is whether bioMérieux's recent sales declines in North America and Asia are temporary (like a slow flu season) or permanent (like losing customers to better competitors), which its earnings report in late July 2026 should clarify.

Why

AI pressure: None apparent. AI tools like bioMerieux's own Day Zero and the Mila partnership predict resistance, they don't replace the wet-lab hardware that runs the test. Could AI do the core job? Unlikely.

Bigger players: Abbott and Roche in immunoassays and point-of-care testing. Point-of-care troponin and PCT tests from Abbott and Roche are pulling volume from bioMerieux's immunoassay line, down 6% in 2025. Could a giant copy it? No, they are blocked.

What protects it. Thousands of installed BIOFIRE and SPOTFIRE machines lock hospitals into bioMerieux's own reagents, and FDA/CE clearance makes switching slow.

What would change this call

bioMérieux H1 2026 results (due July 28, 2026) show North America organic sales still down >5%. would indicate structural share loss rather than a one-off cyclical dip.
Immunoassay segment revenue growth turns positive in H1 or Q3 2026 filings. would show the Abbott/Roche point-of-care pressure is easing, not worsening.
Cepheid (Danaher) or Roche publicly reports syndromic PCR installed-base wins displacing BIOFIRE customers. would confirm direct customer loss in bioMérieux's core respiratory panel franchise.

Key numbers

FY2025 net sales: 4.07 billion euros (2025-12-31)
SPOTFIRE revenue up 84% to 168 million euros (2025-12-31)
North America organic sales down 6.9% in Q1 2026 (2026-04-23)

Named risks

North America organic sales decline (-6.9% in Q1 2026) persisting into H1 2026 results due July 28, 2026. Severity: high
China regulatory and reimbursement policy causing recurring mid-single-digit organic declines. Severity: medium
Immunoassay segment erosion (-6% FY2025) to Abbott and Roche in point-of-care testing. Severity: medium
Multiple 2026 analyst downgrades (UBS, Deutsche Bank, JPMorgan, Morgan Stanley) signal weak near-term visibility. Severity: medium
250 million euro Isère manufacturing capex commitment could pressure margins if execution slips. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Roche Diagnostics	gaining on	Holds roughly 20% of global IVD market as of mid-2026 versus bioMérieux's smaller scale
Abbott	contesting	bioMérieux immunoassay segment fell 6% in FY2025 amid point-of-care competitive pressure
Danaher (Cepheid)	contesting	Competes directly in syndromic PCR against bioMérieux's BIOFIRE platform
DiaSorin	gaining on	Morgan Stanley favored DiaSorin over bioMérieux in EU biopharma stock note, August 2025
BD (Becton Dickinson)	contesting	Named peer across sepsis and point-of-care molecular diagnostics markets

Questions people ask

Is bioMérieux profitable in 2026?: Yes on a full-year basis: FY2025 net income was 397 million euros with free cash flow of 462 million euros. However Q1 2026 sales missed forecasts, triggering a guidance cut and a 15% single-day stock drop on April 23, 2026, raising near-term margin pressure questions.
Could AI replace bioMérieux's diagnostics business?: No. bioMérieux's core products, BIOFIRE, VIDAS and VITEK, are FDA and CE-cleared regulated wet-lab hardware and reagent systems. AI is being layered in as a feature, such as the April 2025 Mila partnership on antimicrobial-resistance prediction, not a replacement for physical diagnostic testing.
Who owns bioMérieux?: Institut Mérieux, the Mérieux family holding company, controls roughly 59% of bioMérieux's share capital and a majority of voting rights as of January 2026, via Compagnie Mérieux Alliance SAS. The company has traded publicly on Euronext Paris under ticker BIM since 2004.
Is bioMérieux stock down in 2026?: Yes, significantly. Shares fell over 15% on April 23, 2026 after a Q1 sales miss and guidance cut, and by July 5, 2026 the stock traded near its 52-week low of about 67.75 euros, down roughly 43% year-over-year from a high of 128.30 euros.
Who is bioMérieux's biggest competitor?: Roche Diagnostics, holding roughly 20% of the global IVD market as of mid-2026, alongside Abbott, Danaher (via Cepheid), BD and DiaSorin. bioMérieux's immunoassay segment fell 6% in FY2025 partly due to point-of-care competition in that space.
Will bioMérieux's H1 2026 results show recovery?: Unclear from prior data alone; H1 2026 results are due July 28, 2026, following a Q1 2026 report that showed North America organic sales down 6.9% and Asia-Pacific down 7.6%, after which full-year guidance was cut and shares fell over 15% on April 23, 2026.

Timeline

2026-06-30Submitted FDA 510(k) for updated BIOFIRE FILMARRAY Gastrointestinal panel
2026-06-01UBS, Deutsche Bank, JPMorgan and Morgan Stanley cut price targets and downgraded ratings
2026-05-29Announced 250 million euro manufacturing investment in Isere, France for PCR tests
2026-04-23Q1 2026 sales miss and guidance cut trigger over 15% single-day stock drop
2026-02-27FY2025 results released: 4.07 billion euro sales, 397 million euro net income
2026-01-22Acquired remaining stake in Accellix for about 35 million euros, reaching 100% ownership
2025-06-01Acquired Day Zero Diagnostics assets for about 25 million US dollars
2025-04-09Announced AI partnership with Mila on antimicrobial-resistance prediction
2025-01-13Acquired SpinChip Diagnostics ASA for 138 million euro enterprise value

Revision history

24 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

DiaSorin S.p.A.Spectris plc Tecan Group